Modified Biotin Streptavidin Mutant Patent - Cancer Treatment
Summary
The European Patent Office published application EP3842440A2 for CompleCure, Inc., covering modified biotin compounds and streptavidin mutants for cancer treatment and diagnostic applications. The patent includes claims related to C07K peptide compositions and therapeutic uses. Designated states cover major European markets including Germany, France, UK, Italy, and Spain.
What changed
The European Patent Office granted patent EP3842440A2 to CompleCure, Inc., covering modified biotin compounds, streptavidin mutants, and their therapeutic applications in cancer treatment. The patent includes multiple IPC classifications spanning peptide chemistry, pharmaceutical compositions, and diagnostic methods. Designated states include all major European Patent Convention member states.\n\nFor biotechnology and pharmaceutical companies, this patent establishes intellectual property protection for biotin-streptavidin based cancer therapeutics. Competitors developing similar compounds should review freedom-to-operate positions. Research institutions may need to consider licensing terms for academic or commercial applications involving these modified compounds.
What to do next
- Monitor for competitive patent activity in biotin-streptavidin space
- Review licensing opportunities for cancer treatment applications
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM
Publication EP3842440A2 Kind: A2 Apr 01, 2026
Applicants
CompleCure, Inc.
Inventors
SUGIYAMA, Akira, DOI, Hirofumi, KODAMA, Tatsuhiko, INOUE, Tsuyoshi, MIZOHATA, Eiichi, KAWATO, Tatsuya, MESHIZUKA, Tomohiro, KANAI, Motomu, SHIMIZU, Yohei, TAKASU, Noriaki, TAKATSU, Mari
IPC Classifications
C07D 519/00 20060101AFI20210601BHEP A61K 39/395 20060101ALI20210601BHEP A61K 49/00 20060101ALI20210601BHEP C07K 14/36 20060101ALI20210601BHEP C12N 15/09 20060101ALI20210601BHEP C07K 16/28 20060101ALI20210601BHEP C12Q 1/68 20180101ALI20210601BHEP G01N 33/53 20060101ALI20210601BHEP A61P 35/00 20060101ALI20210601BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.